Saudi Arabia Continuous Glucose Monitoring Devices Market Size, Share & Forecast, By Product Type, Care Setting & Channel, 2026-2031

The Saudi Arabia Continuous Glucose Monitoring Devices Market is valued at USD 80 million in 2025. The estimate represents domestic revenue from sensors, transmitters, receivers, integrated CGM functionality and directly associated device software, while excluding conventional finger-stick meters and standalone insulin-pump revenue. Supply-side vendor estimates, active-user economics and demand-side diabetes eligibility were weighted to a single base value. The resulting range is USD 68-92 million, with recurring sensor volume accounting for most market value.

The market is forecast to reach USD 180.2 million by 2031, representing a 14.49% CAGR from 2025. Active-user equivalents expand faster, from 70,000 in 2025 to 183,500 in 2031, because competitive pricing, longer sensor wear and institutional procurement reduce revenue per user. Growth is therefore volume led rather than price led. The principal expansion cohorts are insulin-treated type 2 patients, virtual-care users and patients adopting integrated automated insulin delivery systems.

The profit pool will shift from readers and initial hardware toward recurring sensors, subscriptions, clinical dashboards and automated insulin delivery integration. Sensors represented an estimated 76% of 2025 revenue, while software and service economics remained smaller but faster growing. By 2031, lower blended device pricing will make customer lifetime value dependent on replenishment adherence and analytics attachment. Vendors with clinician portals, caregiver sharing, predictive alerts and payer reporting can defend margins better than suppliers competing solely on sensor price.

The largest constraint is the recurring cost of sensors combined with uneven reimbursement interpretation. Although Saudi insurance rules permit coverage of prescribed SFDA-licensed medical devices, formularies, provider networks and authorization processes differ. A patient using 14-day sensors may require roughly 24-26 sensors annually, making persistence sensitive to co-payments and supply continuity. Safety alerts, app settings and patient training add further service requirements, especially for insulin users who depend on real-time alarms.

Saudi Arabia is the largest selected Gulf CGM market, ahead of the UAE, Kuwait, Qatar and Oman in 2025. Its USD 80.0 million size reflects a 5.34 million adult diabetes population, broad national healthcare coverage and a large public procurement system. The UAE has higher purchasing power per capita but a much smaller diabetes population, while Qatar and Oman remain compact markets. Saudi Arabia also carries the strongest localization and remote-monitoring opportunity because user scale can support dedicated Arabic services and national distributor infrastructure.

The most important demand driver is the expansion of CGM from type 1 diabetes into insulin-treated and selected non-intensively managed type 2 populations. Type 1 patients remain the highest-frequency users, but Saudi Arabia's much larger type 2 population determines long-term market scale. Local consensus work, national digital diabetes initiatives and virtual-care capacity improve the case for short-duration diagnostic CGM, medication optimization and remote monitoring. This broadening can multiply the eligible population without requiring all users to wear sensors continuously.